- Home
- OMC vs PODD Comparison
OMC vs PODD Comparison
Compare OMC & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OMC | PODD |
|---|---|---|
| Founded | 1944 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.3B | 21.0B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | OMC | PODD |
|---|---|---|
| Price | $79.54 | $286.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 19 |
| Target Price | $92.83 | ★ $367.32 |
| AVG Volume (30 Days) | ★ 4.1M | 626.8K |
| Earning Date | 02-03-2026 | 02-18-2026 |
| Dividend Yield | ★ 4.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.79 | 3.45 |
| Revenue | ★ $16,065,300,000.00 | $2,521,800,000.00 |
| Revenue This Year | $4.67 | $32.55 |
| Revenue Next Year | $24.99 | $20.47 |
| P/E Ratio | ★ $11.76 | $83.37 |
| Revenue Growth | 4.13 | ★ 27.11 |
| 52 Week Low | $68.37 | $230.05 |
| 52 Week High | $89.35 | $354.88 |
Technical Indicators
Market Signals| Indicator | OMC | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 52.78 | 44.53 |
| Support Level | $76.93 | $275.10 |
| Resistance Level | $79.88 | $299.80 |
| Average True Range (ATR) | 1.99 | 7.48 |
| MACD | -0.17 | 0.77 |
| Stochastic Oscillator | 51.39 | 45.07 |
Price Performance
Historical ComparisonAbout OMC Omnicom Group Inc.
Omnicom is a holding company that owns several advertising agencies and related firms. It provides traditional and digital advertising services that include creative design, market research, data analytics, ad placement, and public relations. The firm operates globally, providing services in more than 70 countries; it generates more than one half of its revenue in North America and nearly 30% in Europe.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.